William F. Feely

Statistics

Publications

Citations

4.9K

H-Index

Active since

1991

Affiliations

Bristol-Myers Squibb (United States)(Current)

Memorial Sloan Kettering Cancer Center

Yale Cancer Center

Merck & Co., Inc., Rahway, NJ, USA (United States)

Georgetown Lombardi Comprehensive Cancer Center

William F. Feely is an author at Bristol-Myers Squibb (United States) specializing in cancer immunotherapy, oncology, and checkpoint inhibitor therapy.

Publications per year

1991–2021

Publications

Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan et al. · New England Journal of Medicine · 2013 · 4.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).

Mario Sznol, Harriet M. Kluger, Margaret K. Callahan et al. · Journal of Clinical Oncology · 2014 · 137 citations

Pharmacy, Oncology, Pharmacotherapy +17

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).

Mario Sznol, Harriet M. Kluger, Margaret K. Callahan et al. · Journal of Clinical Oncology · 2014 · 79 citations

Pharmacy, Oncology, Pharmacotherapy +17

Photodegradation of avermectin B1a thin films on glass

Louis S. Crouch, William F. Feely, Byron H. Arison et al. · Journal of Agricultural and Food Chemistry · 1991 · 52 citations

Natural Sciences, Chemistry, Food Science +9

Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function

Michelle Treitel, Thomas Marbury, Richard A. Preston et al. · Clinical Pharmacokinetics · 2012 · 42 citations

Pharmacy, Pharmacokinetics, Pharmacology +10

1–5 of 18